Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | ARROW: carfilzomib dosing in frail R/R multiple myeloma patients

Maria-Victoria Mateos • 3 Jun 2019
ASCO 2019
Multiple Myeloma Carfilzomib
ARROW

The ARROW study (NCT02412878) investigated the safety and efficacy of once-weekly carfilzomib dosing in frail relapsed/refractory multiple myeloma patients. Maria-Victoria Mateos, MD, PhD, of the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discuses this study at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals